Advances in Type 2 Diabetes: Molecular Mechanisms and Therapeutic Innovations

Dear Colleagues,

The prevalence of Type 2 diabetes is presently increasing at an alarming rate of near-epidemic proportions in numerous global populations, where it has a significant impact on available therapeutic and socioeconomic resources. This is in addition to the medical impact on human health and the impact it has on productivity for those individuals who develop the disorder.  Furthermore, type 2 diabetes is a significant public health concern due to its close link with numerous metabolic comorbidities, such as obesity and overweight conditions, dyslipidemia, renal dysfunction,  and cardiovascular disorders. Evidence suggests that heritable factors, in addition to excessive or inappropriate nutrient intake, contribute to the expression and development of insulin resistance and systemic inflammation, classic hallmarks of the disorder. Costly, long-term pharmacologic and dietary interventions remain the primary strategies for managing type 2 diabetes and its associated metabolic disorders. However,  current strategies seldom bring about curative, lasting results, indicating a need for more effective therapeutic measures likely focused at the molecular or epigenetic level are necessary. In this Special Issue, we plan to explore current advances in Type 2 diabetes, including nutritional factors, molecular mechanisms, sirtuins and other epigenetic factors, and emerging therapeutic innovations to address and resolve the rapidly increasing prevalence of Type 2 diabetes. Nutrient-dense, manufactured foods now represent over 50% of the daily caloric intake in some industrialized nations where Type 2 diabetes is prevalent, and while commercially processed foods are considered generally safe for human consumption, they typically contain greater amounts of dietary fats, salt and other chemical preservatives than wholesome fresh farm-to-table food choices, and pose a greater risk of premature demise when a high proportion of  industrialized food selections are consumed. The contributions of commercially manufactured food consumption to maintaining a healthy gut microbiota also remain unclear. 

In this Special Issue, we aim to cover aspects of molecular,  hormonal, epigenetic,  macro- and micro-nutrient, environmental, and socioeconomic significance, as well as the current dietary and pharmacotherapeutic recommendations. We plan to explore the primary metabolic pathways and molecular mechanisms in which each nutrient or dietary additive contributes a role, and their contribution to the development of Type 2 diabetes and its metabolic comorbidities. Importantly, gut microbiota are also crucial in regulating the metabolic responses to nutrient intake. As such, we also aim to gain a mechanistic understanding of how nutrients, intestinal microbiota and other factors may contribute to the metabolic health of the human host. By doing so, we hope to shed light on the pathogenesis of various common metabolic disorders including, but not limited to, type 2 diabetes, obesity, renal diseases, and cardiometabolic diseases. Thus, this Special Issue will focus on novel strategies, epigenetic mechanisms, and molecular mechanisms, as well as nutritional approaches, to address the ongoing increase in the prevalence of type 2 diabetes and its associated metabolic disturbances. With this, this Special Issue of Biomolecules, entitled “Advances in Type 2 Diabetes: Molecular Mechanisms and Therapeutic Innovations”, aims to solicit original research papers or review articles on the current state of research in this field, including both discovery and preclinical studies.

We look forward to receiving your contributions.

Dr. Orien L. Tulp
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• type 2 diabetes (T2DM)
• insulin resistance
• GLUT4
• sirtuins
• epigenetic expression
• nutrition
• pharmacotherapeutics